Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
Subscribe To Our Newsletter & Stay Updated
